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April 13, 2010:1643–7eceiving usual care (3). Moreover, atorvastatin treatment reduced
composite of total and coronary mortality, coronary morbidity,
nd stroke by 45% (HR: 0.55; 95% CI: 32 to 84, p  0.006) in
atients with preexisting HF (ejection fraction 30%) at baseline
3). In similar patients, the Treating to New Targets study (n 
0,001) results showed that compared with the 10-mg/day dose of
torvastatin, an 80-mg/day dose of atorvastatin in patients with
table IHD significantly reduced hospitalizations for HF (HR:
.74; 95% CI: 0.59 to 0.94; p 0.0116) (4). In a post hoc analysis,
his benefit was only observed in patients with a history of HF
HR: 0.59; 95% CI: 0.4 to 0.88; p  0.009) (4).
Taken together, the data in the preceding text suggest that in
ilder HF, coronary events can be modified by statins and this
ay be the most important driver of outcome. In contrast, in
evere cases of HF, progressive loss of pump function is not
ubstantially improved by statin treatment, especially when admin-
stered in addition to optimal treatment of HF.
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osuvastatin and
ardiovascular Continuum
hen Time Is Important
e read with interest the article by Cleland et al. (1) about
hether N-terminal pro-B-type natriuretic peptide (NT-proBNP)
o
gould be used to identify the degree of severity of heart failure at
hich statins become ineffective in the CORONA (Controlled
osuvastatin Multinational Trial in Heart Failure) trial. Although
any trials have demonstrated that statins reduce cardiovascular
orbidity and mortality in many patients with ischemic heart
isease, this does not seem to occur in those with ischemic heart
ailure, as the CORONA trial showed (2). As a result, there must
e a cutoff point at which treatment with a statin becomes futile.
n this study, the investigators demonstrated that patients in the
owest tertile of NT-proBNP had the best prognosis and, if
ssigned to rosuvastatin rather than placebo, had a greater reduc-
ion in the primary end point (hazard ratio: 0.65; 95% confidence
nterval: 0.47 to 0.88) than patients in the other tertiles (p 
.0192). As a consequence, patients with heart failure due to
schemic heart disease who had NT-proBNP values 103 pmol/l
868 pg/ml) may benefit from rosuvastatin (1).
However, this seems to occur not only in the ischemic heart
isease, but in the overall cardiovascular continuum, and the
ifferent results obtained with rosuvastatin in the different scenar-
os of several randomized clinical trials clearly exemplify it (3).
ardiovascular disease is a continuum, from risk factors to organ
amage and finally to overt clinical cardiovascular disease and
nd-stage renal disease. Although it is very relevant to control all
ardiovascular risk factors along the continuum, the beneficial
ffects of therapy are not the same, depending on the stage at
hich the treatment is started. Thus, if statins are prescribed at
arlier stages, the improvement in cardiovascular prognosis will be
arkedly higher than in later stages (3). For example, in the
UPITER trial (Justification for the Use of Statins in Primary
revention: An Intervention Trial Evaluating Rosuvastatin) (4),
hich included patients without cardiovascular disease but with
levated high-sensitivity C-reactive protein levels, the benefits of
reatment with rosuvastatin were outstanding. However, at very
dvanced stages such as heart failure (CORONA) (2) or at
nd-stage renal disease (AURORA [A Study to Evaluate the Use
f Rosuvastatin in Subjects on Regular Hemodialysis: An Assess-
ent of Survival and Cardiovascular Events]) (5), the benefits were
ery modest or even null. However, even at advanced stages, as
leland et al. (1) reported, not all the patients are the same. Because
ortality is very high, all the approaches aimed at differentiating
hich patients will benefit more from available therapies are crucial.
n this case, NT-proBNP values could likely be used as a good
redictor of the clinical results with a statin therapy.
All these data emphasize that to really improve a cardiovascular
rognosis, it is critical to start the treatment with statins as soon as
ossible in the cardiovascular continuum. If the therapy starts when a
atient is already at end-stage disease, it is most likely too late.
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eply
he CORONA (Controlled Rosuvastatin Multinational Trial in
eart Failure) study included a prespecified subgroup analysis
omparing outcomes in the two-thirds of patients at lower risk
ersus the one-third at higher risk (1). This showed a trend toward
reater benefit in patients with lower plasma N-terminal pro–B-
ype natriuretic peptide (NT-proBNP). Further analysis showed
hat this was driven by a substantial reduction in events in patients
ssigned to rosuvastatin in the lowest third of NT-proBNP (2).
here was no inconsistency between the analyses, as implied by
thyros et al.
The effect of statins in patients with milder heart failure may be
class effect. The subgroup analysis of the Treat to New Targets
tudy (3) suggesting benefit with atorvastatin should be interpreted
ith care because 47% of these 781 patients did not even require
iuretic treatment. The Treat to New Targets study provides no
vidence to support treating moderate or severe heart failure with
tatins. However, the lack of an adverse effect on outcome and the
eduction in hospitalization, even in patients in the highest third of
T-proBNP in the CORONA study provide no compelling
eason to withdraw statins as heart failure progresses other than to
educe polypharmacy. Rosuvastatin may be similarly effective in
educing the progression of vascular disease regardless of heart
ailure severity, but progression by other mechanisms may be the
ain driver of prognosis in patients with more severe heart failure.
We agree with the view of Drs. Barrios and Escobar and Dr.
thyros and colleagues that it is better to start statins in patients
ith or at substantial risk of the development of atheroma, long
efore the development of severe disease such as heart failure or
nd-stage kidney disease, another condition for which both ator-
astatin and rosuvastatin failed to provide clinical benefit (4). Some
atients are probably too well to benefit from statins and others too
ick. The largest treatment effect is likely to be in the mid-range of
isease severity in any target group (5). However, for the most part,
reatment of cardiovascular risk should be considered useful
rocrastination rather than prevention. Prevention implies that a
roblem has been solved and is no longer of concern. The onset of
eart failure may be delayed by modern treatment, but its overall
ncidence or prevalence does not seem to be decreasing; indeed,
odern therapy may be fueling the epidemic. Finding better ways
o manage heart failure should remain a high priority for the
esearch community. pJohn G. F. Cleland, MD
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T-Segment Resolution and
utcome in Myocardial Infarction
ejersten et al. (1) explore the relationship between ST-segment
ecovery and outcome among patients enrolled in the DANAMI
DANish trial in Acute Myocardial Infarction)-2 study (1). In
eneral, their report joins a chorus of others establishing the
alidity of ST-segment recovery as a correlate of myocardial
eperfusion and predictor of outcomes among early ST-segment
levation myocardial infarction survivors. A key finding empha-
ized as “provocative,” however, was the absence of a relationship
inking ST-segment recovery to 30-day mortality among the
ubset of 602 patients assigned to primary percutaneous coronary
ntervention (PCI) in contrast to their fibrinolytic-treated patients.
Before accepting their call for further study, we suggest that
hey first reflect on previous work. A 2004 report of 700 patients
nrolled in the CADILLAC (Controlled Abciximab and Device
nvestigation to Lower Late Angioplasty Complications) trial
evealed a significant relationship between ST-segment recovery
n electrocardiograms acquired within 4 h of PCI (average 1.77 h)
nd both 30-day and 1-year mortality (2). We reported the relation-
hip between early ST-segment recovery (mean 32 min post-primary
CI) and 90-day mortality in 4,866 primary PCI patients enrolled in
he APEX-AMI (Assessment of the PEXilizumab in Acute Myo-
ardial Infarction) trial (3). Six previously published methods for
escribing ST-segment recovery were tested, including ST ele-
ation recovery; all provided robust prognostic information that
ersisted after adjustment for baseline variables and exclusion of
